Personalis Inc (OQ:PSNL)

Business Focus: Biotechnology & Medical Research

Mar 28, 2024 04:01 pm ET
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10 at 1:30 p.m. Eastern Time.
Mar 28, 2024 09:00 am ET
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that a podium talk and multiple abstracts featuring data for the company’s NeXT Personal® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California, April 5-10, 2024.
Mar 26, 2024 09:00 am ET
Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a new publication validating the company’s NeXT Personal test, an ultra-sensitive, tumor-informed circulating tumor DNA (ctDNA) assay. NeXT Personal is designed to help detect minimal residual disease (MRD), monitor therapy response, and identi
Mar 19, 2024 04:43 pm ET
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on November 15, 2023 and March 15, 2024, non-qualified stock options to purchase an aggregate of 41,500 shares of its common stock to ten new employees under Personalis’ 2020 Inducement Plan.
Feb 28, 2024 04:01 pm ET
Personalis Reports Fourth Quarter and Full Year 2023 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights.
Feb 14, 2024 04:01 pm ET
Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.
Jan 31, 2024 04:01 pm ET
Personalis to Participate at Upcoming Investor Conferences
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the following investor conferences:
Jan 30, 2024 09:00 am ET
Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, and ClearNote Health
Jan 17, 2024 04:15 pm ET
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted non-qualified stock options to purchase an aggregate of 29,000 shares of its common stock to eight new employees under Personalis’ 2020 Inducement Plan.
Jan 16, 2024 09:05 am ET
Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced it has received a final Medicare coverage determination for its NeXT Dx ultra-comprehensive tumor genomic profiling assay, providing access for the nation’s 66 million Medicare and Medicare Advantage beneficia
Jan 05, 2024 09:05 am ET
Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2023.
Dec 04, 2023 09:15 am ET
Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives
Personalis, Inc., a leader in advanced genomics for precision oncology (Nasdaq: PSNL), disclosed a reduction in headcount impacting approximately 20% of the company’s staff. By consolidating several functions for efficiency, this reduction is expected to reduce operating expenses by approximately $14 million annually. This action, along with the
Nov 28, 2023 04:15 pm ET
Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing
Personalis, Inc., a leader in advanced genomics for precision oncology (Nasdaq: PSNL), and Tempus Lab
Nov 07, 2023 04:01 pm ET
Personalis Reports Third Quarter 2023 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2023 and provided recent business highlights.
Oct 26, 2023 08:15 am ET
Personalis Launches NeXT Personal® Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the launch of the Early Access Program for NeXT Personal Dx, a tumor-informed, whole genome-based liquid biopsy laboratory developed test (LDT) for detection of molecular residual disease (MRD) and recurrence in cancer. Designed to help oncologi
Oct 24, 2023 04:01 pm ET
Personalis to Announce Third Quarter 2023 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2023 financial results on Tuesday, November 7, 2023. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.
Oct 21, 2023 04:25 am ET
Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology
Personalis, Inc. (Nasdaq: PSNL), a leader in precision oncology, today announced the presentation of initial findings from its work with the groundbreaking TRACERx lung cancer study, marking a substantial advancement in lung cancer circulating tumor DNA (ctDNA) detection and management. The Personalis NeXT Personal cancer assay, created to detect
Oct 19, 2023 07:15 am ET
Personalis Announces Late-Breaking NeXT Personal Abstract and Proffered Paper Presentation at ESMO 2023
Personalis, Inc. (Nasdaq: PSNL), a leader in precision oncology, today announced that a late-breaking abstract featuring data for the company’s NeXT Personal® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection, has been accepted and selected for a proffered paper presentation at the 2023 European Society for M
Oct 18, 2023 07:15 am ET
Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomic testing for precision oncology, today announced the appointment of Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance. With over two decades of industry marketing and regulatory affairs experience, Ms. Bhandari will help the company navigate the regulatory requirem
Aug 29, 2023 04:01 pm ET
Personalis to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will present at the 21st Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2023 at 4:55 p.m. Eastern Time in New York, NY at the Sheraton New York.
Aug 24, 2023 07:01 pm ET
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the Compensation Committee of its Board of Directors granted, between the dates of May 15, 2023 and August 15, 2023, non-qualified stock options to purchase an aggregate of 43,000 shares of its common stock and restricted stock units (RSUs) covering an aggregate of 24,500 shares of its common stock to sixteen new employees under Personalis’ 2020 Inducement Plan.
Aug 15, 2023 10:20 am ET
Sidoti Events, LLC’s Virtual August Micro-Cap Conference
NEW YORK, NY / ACCESSWIRE / August 15, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place Wednesday and Thursday, August 16-17, 2023. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.
Aug 08, 2023 04:01 pm ET
Personalis Reports Second Quarter 2023 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2023 and provided recent business highlights.
Aug 01, 2023 04:01 pm ET
Personalis to Participate at Upcoming Investor Conferences
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will participate at the following investor conferences:
Jul 25, 2023 04:01 pm ET
Personalis to Announce Second Quarter 2023 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its second quarter 2023 financial results on Tuesday, August 8, 2023. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.
Jun 26, 2023 05:00 pm ET
Personalis Files Second Patent Infringement Suit Against Foresight Diagnostics
Personalis, Inc. (Nasdaq: PSNL) today announced that the company has filed a second patent infringement suit against Foresight Diagnostics Inc. Personalis is seeking injunctive relief and monetary damages. This suit brings the total number of patents that Personalis alleges Foresight Diagnostics has infringed to seven.
Jun 13, 2023 07:01 pm ET
Dr. Kenneth J. Widder Joins Personalis Board of Directors
Personalis, Inc. (Nasdaq: PSNL) today announced that it has appointed Kenneth J. Widder, M.D., to its Board of Directors.
May 30, 2023 08:00 am ET
Personalis Announces Two Abstracts Accepted for Presentation at ASCO 2023
Personalis, Inc. (Nasdaq: PSNL) today announced it will present new clinical data as scientific posters at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023, which convenes from June 2-6, 2023, in Chicago, Ill.
May 16, 2023 08:00 am ET
Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer
Personalis, Inc. (Nasdaq: PSNL), National Cancer Center, and Ono Pharmaceutical Co., Ltd. today announced they have entered into a collaborative agreement to examine the efficacy and safety of nivolumab, an immune checkpoint inhibitor, for resectable rectal cancer with mismatch repair deficiency (dMMR). As part of the collaboration on the VOLTAGE-2 study, an exploratory analysis will be conducted to evaluate specific biomarkers such as minimal residual disease (MRD) status that may have prognostic or predictive value for patient care.
May 03, 2023 04:01 pm ET
Personalis Reports First Quarter 2023 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter ended March 31, 2023 and provided recent business highlights.
May 02, 2023 08:00 am ET
Personalis, ABRCC, and Criterium Announce Major Prospective Clinical Trial for Residual and Recurrent Disease Detection in Triple Negative Breast Cancer
Personalis, Inc. (Nasdaq: PSNL) today announced it has partnered with the Academic Breast Cancer Consortium (ABRCC) and Criterium to carry out a prospective clinical trial, B-STRONGER-1 (Breast Cancer-Minimal Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I), to evaluate the clinical performance of the
Apr 19, 2023 04:01 pm ET
Personalis to Announce First Quarter 2023 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its first quarter 2023 financial results on Wednesday, May 3, 2023. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.
Apr 05, 2023 04:01 pm ET
Personalis to Participate at the 22nd Annual Needham Virtual Healthcare Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19 at 3:00 p.m. Eastern Time.
Apr 05, 2023 08:45 am ET
Personalis Joins Top UK Cancer Research Organizations to Evaluate Earlier Cancer Recurrence Detection Through Groundbreaking Study
Personalis, Inc. (Nasdaq: PSNL), Cancer Research UK’s Cancer Research Horizons, University College London (UCL), and the Francis Crick Institute today announced a collaboration to deploy NeXT Personal, a personalized liquid biopsy-based research assay, for the TRACERx study, a groundbreaking lung cancer initiative funded by Cancer Res
Mar 22, 2023 08:55 am ET
Personalis Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting 2023
Personalis, Inc. (Nasdaq: PSNL) today announced it is presenting new research data as scientific posters at the American Association for Cancer Research (AACR) Annual Meeting 2023, which convenes from April 14-19, 2023 in Orlando, Florida.
Mar 07, 2023 08:55 am ET
Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced it will continue its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), a global science-led biopharmaceutical company, to explore ultra-sensitive molecular residual disease (MRD) measurement, including clinically relevant and personalized variant tracking, for clinical research and drug development.
Mar 02, 2023 04:05 pm ET
Personalis Appoints Christopher Hall as Chief Executive Officer
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that its Board of Directors has appointed Christopher Hall as Chief Executive Officer (CEO) and a member of the Board, effective immediately, in addition to his role as President. Hall will lead the Company’s efforts to drive a new paradigm for the active management of cancer with the aim of guiding care from biopsy throughout the life of the patient. Hall joined Personalis in October 2022 and became President at the end of December 2022.
Feb 23, 2023 04:01 pm ET
Personalis Reports Fourth Quarter and Full Year 2022 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided recent business highlights.
Feb 09, 2023 04:01 pm ET
Personalis to Announce Fourth Quarter and Full Year 2022 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its fourth quarter and full year 2022 financial results on Thursday, February 23, 2023. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.
Feb 06, 2023 04:01 pm ET
Personalis to Participate at Upcoming Investor Conferences
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the following investor conferences:
Feb 03, 2023 08:45 am ET
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the companies have signed a new agreement to continue using the Personalis NeXT Platform® as part of upcoming clinical studies evaluating mRNA-4157/V940, an investigational personalized cancer vaccine, jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada. The platform, which was also utilized in the vaccine candidate’s P
Jan 04, 2023 04:01 pm ET
Personalis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2022.
Dec 16, 2022 04:05 pm ET
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the Compensation Committee of its Board of Directors granted, between the dates of December 5, 2022 and December 16, 2022, non-qualified stock options to purchase an aggregate of 35,000 shares of its common stock and restricted stock units (RSUs) covering an aggregate of 42,100 shares of its common stock to three new employees under Personalis’ 2020 Inducement Plan.
Dec 14, 2022 04:02 pm ET
Personalis Announces CEO Retirement and Transition
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that John West, co-founder, CEO and member of the board of directors of Personalis, notified the Company of his decision to retire as CEO and a director at the end of the calendar year. Mr. West has served in the DNA sequencing field for over forty years, and co-founded Personalis with four Stanford professors in 2011.
Nov 30, 2022 08:55 am ET
Personalis and UCSF to Study Clinical Utility of ctDNA for Treatment Response in Colorectal Cancer
Personalis, Inc. (Nasdaq: PSNL) today announced a collaboration with UC San Francisco (UCSF) that will deploy a personalized liquid biopsy-based research use only (RUO) assay for a study of patients with colorectal cancer. The research efforts will use Personalis’ NeXT Personal™ assay to evaluate circulating tumor DNA (ctDNA)-based si
Nov 21, 2022 04:01 pm ET
Personalis to Present at the 34th Annual Piper Sandler Healthcare Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 34th Annual Piper Sandler Healthcare Conference on Wednesday, November 30, 2022 at 1:30 p.m. Eastern Time in New York, NY.
Nov 07, 2022 04:05 pm ET
Personalis Presents Data from New Platform Features at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Personalis, Inc. (Nasdaq: PSNL) today announced that the company will share data resulting from expanded features of its NeXT Platform® at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 8-12 in Boston, with three abstracts that highlight advanced R&D applications of ne
Nov 02, 2022 04:01 pm ET
Personalis Reports Third Quarter 2022 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2022.
Oct 31, 2022 04:16 pm ET
Personalis Grows Leadership Team with Appointment of Christopher Hall as Senior Vice President and Head, Diagnostics Business
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the appointment of Christopher Hall as SVP and Head, Diagnostics Business. As part of the executive leadership team, Hall will drive the vision and strategy for commercializing Personalis’ diagnostic product offerings.
Oct 19, 2022 04:01 pm ET
Personalis to Announce Third Quarter 2022 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2022 financial results on Wednesday, November 2, 2022. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.
Oct 04, 2022 09:00 am ET
Personalis Forms Research Collaboration to Better Predict Immunotherapy Response for Gastroesophageal Cancer
Personalis, Inc. (Nasdaq: PSNL) has joined with Duke University and Olink Proteomics AB to form a research collaboration to study the effects of immunotherapy on advanced gastroesophageal cancer. Specifically, the collaboration will focus on identifying composite biomarkers—those that integrate multiple biological entities into a single readout—to help guide therapeutic decision making.
Aug 30, 2022 04:01 pm ET
Personalis to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022 at 1:30 p.m. Eastern Time in New York, NY.
Aug 17, 2022 04:15 pm ET
Personalis Adds New MRD Patent Covering the Combination of Tumor-Informed and Database-Derived Content to Patent Infringement Complaint Against Foresight Diagnostics
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it has filed an amended complaint against Foresight Diagnostics. The amended complaint asserts a newly-issued patent in Personalis’ growing intellectual property portfolio relating to detection of molecular residual disease (MRD).
Aug 16, 2022 04:05 pm ET
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that, effective on August 15, 2022, the Compensation Committee of its Board of Directors granted non-qualified stock options to purchase an aggregate of 70,000 shares of its common stock and restricted stock units (RSUs) covering an aggregate of 70,000 shares of its common stock to two new employees under Personalis’ 2020 Inducement Plan.
Aug 15, 2022 08:55 am ET
Personalis in Partnership with BC Cancer to Assess Clinical and Economic Benefits of ctDNA for Colorectal and Pancreatic Cancers
Personalis, Inc. has announced a collaboration with BC Cancer to deploy a personalized liquid biopsy-based research use only (RUO) assay for a study of patients with colorectal and pancreatic cancers. The research efforts will deploy Personalis’ NeXT Personal, which has demonstrated high sensitivity for detecting circulating tumor DNA
Aug 04, 2022 04:01 pm ET
Personalis to Participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on Tuesday, August 16, 2022.
Aug 03, 2022 04:01 pm ET
Personalis Reports Second Quarter 2022 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2022.
Aug 02, 2022 04:10 pm ET
Personalis Files Patent Infringement Lawsuit Against Foresight Diagnostics
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it filed a lawsuit against Foresight Diagnostics Inc. for infringement of Personalis’ U.S. Patent Nos. 10,450,611, 11,299,783, and 11,384,394. These patents are part of Personalis’ intellectual property portfolio in the field of whole genome-enabled, tumor-informed molecular residual disease (MRD) testing.
Jul 20, 2022 04:01 pm ET
Personalis to Announce Second Quarter 2022 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its second quarter 2022 financial results on Wednesday, August 3, 2022. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.
Jul 12, 2022 04:05 pm ET
Personalis Announces Expansion of Its Patent Portfolio Related to Tumor-Informed Detection of Molecular Residual Disease
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, has added another patent family to its molecular residual disease (MRD)-related IP portfolio, with priority to January 2013.
May 04, 2022 04:01 pm ET
Personalis Reports First Quarter 2022 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter ended March 31, 2022.
Apr 28, 2022 04:01 pm ET
Personalis to Present at Upcoming Investor Conferences
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the following investor conferences:
Apr 26, 2022 08:45 am ET
Evaxion to Utilize Personalis’ ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage Melanoma
Evaxion Biotech A/S (Nasdaq: EVAX) and Personalis (Nasdaq: PSNL) announced today that Evaxion will deploy Personalis’ ImmunoID NeXT Platform in a Phase 2b trial to evaluate the efficacy and safety of Evaxion’s personalized cancer immunotherapy EVX-01. The study will combine EVX-01, a neoepitope-targeting immunotherapy based on Evaxion’s proprietary PIONEER® AI technology, with KEYTRUDA® (pembrolizumab) for the treatment of patients with metastatic melanoma.
Apr 21, 2022 09:00 am ET
Personalis Expands Diagnostic Leadership Team With Appointment of James Azzaro, Vice President of Diagnostic Sales
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the appointment of James Azzaro to the newly created position of Vice President of Diagnostic Sales. This appointment supports the company’s objective to accelerate expansion into the clinical market.
Apr 20, 2022 04:01 pm ET
Personalis to Announce First Quarter 2022 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2022 financial results on Wednesday, May 4, 2022. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.
Apr 12, 2022 08:55 am ET
Personalis Publishes New Data Demonstrating Highly Sensitive Algorithm for Detecting Loss of Heterozygosity in HLA Gene
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of its study titled, "A machine learning algorithm with subclonal sensitivity reveals widesp
Apr 12, 2022 08:30 am ET
Personalis Announces Issuance of Additional US Patent Related to the NeXT Personal™ Platform
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced the issuance of a key US Patent related to its industry-leading minimal residual disease (MRD) and recurrence platform, NeXT Personal.
Apr 11, 2022 09:00 am ET
Personalis and Merck KGaA, Darmstadt, Germany to Present Comprehensive Tumor Subtyping Collaboration Data at AACR Annual Meeting 2022
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced its co-authorship of a study with Merck KGaA, Darmstadt, Germany, a leading science and technology company, to be presented during the American Association for Cancer Research Annua
Mar 31, 2022 04:01 pm ET
Personalis to Present at the 21st Annual Needham Virtual Healthcare Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 2:15 p.m. Eastern Time.
Mar 24, 2022 06:25 pm ET
Diagnostic Industry Veteran Karin Eastham to Chair Personalis Board of Directors
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that Karin Eastham has been appointed as Personalis’ new Board Chair effective as of Personalis’ Annual Meeting of Stockholders on May 17, 2022. Ms. Eastham joined the Personalis Board in 2019 and has chaired both its Audit and Nominating and Corporate Governance Committees. Ms. Eastham earlier served on the Illumina Board, from 2004 to 2019. During that time Illumina acquired Solexa and became the world leader in DNA sequencing, and also launched multiple initiatives enabling its customers t
Mar 23, 2022 09:01 am ET
Personalis to Present Data Demonstrating Breadth of NeXT Platform for Oncology at AACR Annual Meeting 2022
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced it is presenting new data in scientific posters at the American Association for Cancer Research (AACR) Annual Meeting 2022, which will be held in-person and online, A
Feb 24, 2022 04:01 pm ET
Personalis Reports Fourth Quarter and Full Year 2021 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2021.
Feb 23, 2022 04:01 pm ET
Personalis to Present at the Cowen 42nd Annual Health Care Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022 at 2:10 p.m. Eastern Time.
Feb 15, 2022 08:08 am ET
Personalis Announces Collaboration with UC San Diego Moores Cancer Center for Clinical Genomic Testing and Research into Composite Biomarkers and Minimal Residual Disease Detection
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a strategic collaboration with the Moores Cancer Center at University of California San Diego Health, a National Cancer Institute-designated Comprehensive Cancer Center, to support clinical diagnostic testing in patients with advanced solid tumors and hematological malignancies. The collaboration will bring Personalis’ leading comprehensive genomic tumor profiling test to UC San Diego health care professionals and their cancer patients to help guide FDA-approved therapy decisions, as well as
Feb 10, 2022 04:01 pm ET
Personalis to Announce Fourth Quarter and Full-Year Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full-year 2021 financial results on Thursday, February 24, 2022. In conjunction with the release, the company will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.
Feb 01, 2022 04:01 pm ET
Personalis to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 15, 2022 at 2:00 p.m. Eastern Time.
Jan 06, 2022 04:01 pm ET
Personalis Reports Preliminary Fourth Quarter and Full Year 2021 Revenue
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer and population sequencing, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2021.
Dec 28, 2021 04:01 pm ET
Personalis to Participate in the 24th Annual Needham Virtual Growth Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management will participate in the 24th Annual Needham Virtual Growth Conference on Tuesday, January 11, 2022.
Dec 16, 2021 08:45 am ET
Personalis Launches NeXT Personal™, A Tumor-Informed Liquid Biopsy Assay for MRD and Recurrence Detection With Part-Per-Million Sensitivity
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of NeXT Personal, a next-generation, tumor-informed liquid biopsy assay designed to detect and quantify molecular residual disease (MRD) and recurrence in patients previously diagnosed with cancer. NeXT Personal delivers industry-leading MRD sensitivity down to the 1 part-per-million range, an approximately 10- to 100-fold improvement over other available technologies. This enables earlier detection across a broader variety of cancers and stages, including typically challenging early stage, lo
Nov 18, 2021 04:26 pm ET
Personalis to Participate in the 33rd Annual Piper Sandler Virtual Healthcare Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management will participate in the 33rd Annual Piper Sandler Virtual Healthcare Conference on Wednesday, December 1, 2021.
Nov 12, 2021 09:03 am ET
Personalis Named to Inc.'s 2021 Best-Led Companies List
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that it has been named to Inc.’s inaugural 2021 Best-Led Companies list — a select, data-driven list of U.S.-based companies with the strongest management excellence and revenue of $50 million to $2 billion. Personalis wa
Nov 11, 2021 04:05 pm ET
Personalis to Present New Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 12-14, including online poster presentations and online industry sponsored symposium.
Nov 04, 2021 07:00 am ET
Personalis Reports Third Quarter 2021 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer and population sequencing, today reported financial results for the third quarter ended September 30, 2021.
Nov 02, 2021 07:01 pm ET
Personalis Announces Updates to NeXT Platform™ Incorporating Additional Key Profiling Capabilities for Advancing Oncology Biomarkers
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the latest expansion of the Personalis NeXT Platform® adding several new features that are key to the understanding of the interactions between the tumor and the immune system and how they may influence a cancer p
Oct 26, 2021 05:45 pm ET
Personalis Announces Issuance of US Patents Related to the Exome-Wide NeXT Liquid Biopsy Platform
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the issuance of two key US Patents related to its high-performance, exome-wide liquid biopsy platform, NeXT Liquid Biopsy™.
Oct 26, 2021 04:25 pm ET
Personalis Publishes New Data Demonstrating Performance and Utility of SHERPA for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Development
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the publication of its study “Precision neoantigen discovery using large-scale immunopeptidomes and composite modeling of MHC peptide presentati
Oct 21, 2021 09:00 am ET
Personalis to Announce Third Quarter Financial Results on November 4, 2021
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it will release its third quarter 2021 financial results before the market opens on Thursday, November 4, 2021. In conjunction with the release, the company will host a conference call and webcast that day at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its financial results and recent highlights.
Oct 13, 2021 09:03 am ET
Personalis Expands Leadership Team With Appointment of Robert Bruce, Vice President of Reimbursement
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the appointment of Robert Bruce to the newly created position of Vice President of Reimbursement.
Oct 12, 2021 09:10 am ET
Mayo Clinic Collaborates With Personalis Inc. to Expand Cancer Genomic Testing
Mayo Clinic announced an agreement on Tuesday, Oct. 12 that will allow it to offer clinical-grade comprehensive cancer genomic sequencing to cancer patients who choose to participate. Test results will be available to patients and their treating health care providers to guide therapeutic decisions, advance cancer research, and support the development of new diagnostic tests and therapies for cancer treatment.
Sep 18, 2021 10:50 pm ET
Personalis Receives New VA MVP Task Order and Record Quarterly Orders From Oncology Customers; Reconfirms Total Revenue Outlook for 2021 with Further Accelerated Oncology Growth
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP) has issued a new task order under its current contract with the company, with a value of up to approximately $10 million. The company also announced that it has received, so far in Q3, more than $25M in orders from its oncology customers, a new record. Together these orders allow the company to reconfirm its total revenue outlook for 2021, with oncology revenue growth now projected to be at least 50% a
Aug 26, 2021 04:01 pm ET
Personalis to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the Morgan Stanley 19th Annual Global Healthcare Conference on Thursday, September 9, 2021 at 3:30 p.m. Eastern Time.
Aug 25, 2021 04:01 pm ET
Personalis Announces Corporate Headquarters Expansion to Accelerate Growth in Laboratory Operations and Research & Development
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will relocate both its corporate headquarters and the Personalis Clinical Laboratory from Menlo Park to 6600 Dumbarton Circle in Fremont. The new facility will support the Company's future growth plans and provide greater capacity for laboratory operations and research & development activities. The relocation of the Company’s corporate headquarters to this new facility is expected to occur within the next 12 months.
Aug 04, 2021 04:01 pm ET
Personalis Reports Second Quarter 2021 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer and population sequencing, today reported financial results for the second quarter ended June 30, 2021.
Aug 03, 2021 04:01 pm ET
Personalis to Participate at the 6th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the 6th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 17, 2021.
Aug 02, 2021 04:05 pm ET
Personalis, Inc. Publishes New Data Demonstrating a Novel Composite Biomarker NEOPS™ for Predicting Response to Cancer Immunotherapy in Late-Stage Melanoma Patients
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced translational genomics and diagnostics for cancer, today announced the publication of its study "Prediction of immunot
Jul 21, 2021 04:01 pm ET
Personalis to Announce Second Quarter Financial Results on August 4, 2021
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it will release its second quarter 2021 financial results after the market closes on Wednesday, August 4, 2021. In conjunction with the release, the Company will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.
Jun 22, 2021 09:01 am ET
Personalis Announces NeXT Level Biomarkers Symposium
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced its inaugural event, NeXT Level Biomarkers Symposium, which will showcase novel research into emerging biomarkers using the
Jun 02, 2021 04:03 pm ET
Personalis Announces Delivery of the 125,000th Genome to the U.S. Department of Veterans Affairs Million Veteran Program
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, announced today that it has delivered the 125,000th whole human genome sequence dataset to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP).
May 18, 2021 04:01 pm ET
Personalis to Participate at the Oppenheimer MedTech, Tools & Diagnostics Summit
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the Oppenheimer MedTech, Tools & Diagnostics Summit on Wednesday, May 26, 2021.
May 17, 2021 08:01 am ET
Personalis, Inc. to Present at Biomarkers Week Online 2021
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present at Biomarkers Week Online 2021.
May 05, 2021 04:01 pm ET
Personalis Reports First Quarter 2021 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported financial results for the first quarter ended March 31, 2021.
Apr 29, 2021 04:01 pm ET
Personalis to Present at the 2021 Bank of America Healthcare Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 2021 Bank of America Healthcare Conference on Thursday, May 13, 2021 at 5:00 p.m. Eastern Time.
Apr 21, 2021 04:01 pm ET
Personalis to Report First Quarter 2021 Financial Results on May 5, 2021
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it will release its first quarter 2021 financial results after the market closes on Wednesday, May 5, 2021. In conjunction with the release, the Company will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.
Apr 08, 2021 04:07 pm ET
Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform®
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present new data in scientific posters to be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will be held online, April 10-15, 2021 and May 17-21, 2021.
Mar 29, 2021 04:03 pm ET
Personalis Announces Collaboration with MapKure to Use Personalis’ NeXT Platform™ for Clinical Trials and Companion Diagnostic Development
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced a collaboration with MapKure, LLC, a clinical-stage company focusing on genetically defined disease drivers and jointly owned by BeiGene, Ltd. and SpringWorks Therapeutics, Inc., to use a clinical trial assay (CTA) based on the Personalis® NeXT Platform™, an exome/transcriptome scale NGS-based assay, to support development of BGB-3245, an investigational next-generation B-RAF inhibitor, in patients with advanced or refractory solid tumors.
Mar 08, 2021 05:00 pm ET
Personalis Announces Changes to its Board of Directors
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that it has appointed Dr. Woodrow (Woody) Myers to its Board of Directors and to the Nominating and Corporate Governance Committee of the Board. The company also announced that Patrick J. Balthrop has resigned his position as a director of the company, effective March 8, 2021.
Feb 25, 2021 04:01 pm ET
Personalis Reports Fourth Quarter and Full Year 2020 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported financial results for the fourth quarter and full year ended December 31, 2020.
Feb 22, 2021 08:48 pm ET
CORRECTING and REPLACING Personalis to Report Fourth Quarter 2020 Financial Results on February 25, 2021
Second paragraph, first sentence of release dated February 11, 2021, should read: Interested parties may access the live call via telephone by dialing (866) 220-8061 for domestic callers or (470) 495-9168 for international callers, using conference ID: 5065084. (instead of Interested parties may access the live call via telephone by dialing (866) 990-1997 for domestic callers or (470) 495-9127 for international callers, using conference ID: 5065084.).
Feb 17, 2021 09:01 am ET
Natera and Personalis Partner for Personalized Monitoring in Oncology
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, and Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced that the two companies have entered into a partnership in the field of personalized oncology. The partnership will pair Personalis’ NeXT tumor profiling and diagnostic products with Natera’s personalized ctDNA platform Signatera™ for treatment monitoring and molecular residual disease (MRD) assessment.
Feb 17, 2021 08:00 am ET
Natera and Personalis Partner for Personalized Monitoring in Oncology
SAN CARLOS, Calif. and MENLO PARK, Calif., Feb. 17, 2021 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA testing, and Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the two companies have entered into a partnership in the field of personalized oncology. The partnership will pair Personalis' NeXT tumor profiling and diagnostic products with Natera's personalized ctDNA platform Signatera™ for treatment monitoring and molecular residual disease (MRD) assessment.
Feb 16, 2021 04:01 pm ET
Personalis to Present at Upcoming Investor Conferences
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the following upcoming investor conferences:
Feb 11, 2021 04:01 pm ET
Personalis to Report Fourth Quarter 2020 Financial Results on February 25, 2021
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it will release its fourth quarter 2020 financial results after the market closes on Thursday, February 25, 2021. In conjunction with the release, the Company will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.
Feb 08, 2021 05:13 pm ET
Personalis Expands Leadership Team with Appointment of Susan Moriconi, VP of People and Chief Human Resources Officer
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced the appointment of Susan Moriconi as VP of People and Chief Human Resources Officer.
Feb 04, 2021 04:01 pm ET
Personalis to Present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Thursday, February 18, 2021 at 12:00 p.m. Eastern Time.
Jan 26, 2021 10:09 pm ET
Personalis Announces Pricing of Public Offering of Common Stock
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced the pricing of its previously announced underwritten public offering of 3,950,000 shares of its common stock at a price to the public of $38.00 per share. Gross proceeds to Personalis from the offering are expected to be $150.1 million, before deducting underwriting discounts and commissions and estimated offering expenses.
Jan 26, 2021 04:31 pm ET
Personalis Announces Launch of Public Offering of Common Stock
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that it has commenced an underwritten public offering of $150.0 million of its common stock. In addition, Personalis expects to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of common stock on the same terms and conditions.
Jan 11, 2021 04:01 pm ET
Personalis Reports Preliminary Fourth Quarter 2020 Revenue
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2020.
Dec 28, 2020 04:01 pm ET
Personalis to Present at the 23rd Annual Needham Virtual Growth Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that management will present at the 23rd Annual Needham Virtual Growth Conference on Wednesday, January 13, 2021 at 2:45 p.m. Eastern Time.
Dec 17, 2020 09:09 am ET
Personalis Announces the Launch of NEOPS™, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of its proprietary Neoantigen Presentation Score (NEOPS). NEOPS combines analysis from Personalis’ state-of-the-art tumor neoantigen prediction tool, SHERPA™, with mechanisms of immune evasion to better predict response to cancer therapy.
Dec 17, 2020 09:07 am ET
Personalis Announces the Launch of SHERPA™ for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Development
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of its Systematic HLA Epitope Ranking Pan Algorithm (SHERPA), the company’s proprietary, machine learning-based tool for the comprehensive identification and characterization of cancer neoantigens. Integrated into the Personalis® NeXT Platform™, SHERPA enables the development of new neoantigen-based diagnostic biomarkers, such as the company’s proprietary Neoantigen Presentation Score (NEOPS™), and novel personalized therapies.
Dec 09, 2020 04:07 pm ET
Personalis Announces Delivery of the 100,000th Genome to the U.S. Department of Veterans Affairs Million Veteran Program
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, announced today that it has delivered the 100,000th whole human genome sequence dataset to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). Although Personalis has been contracted by the VA MVP since 2012, the program has accelerated and over 50,000 of these genomes have been delivered in 2020.
Nov 18, 2020 08:00 am ET
Personalis, Inc. to Present at EACR Liquid Biopsies Virtual Event
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that the company will participate in the EACR Liquid Biopsies Virtual Event, November 18-19, including a poster presentation and satellite symposia.
Nov 16, 2020 09:00 am ET
Personalis® to Present at the AMP Annual Meeting 2020
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present data from its clinical test - NeXT DxTM - at the virtual AMP Annual Meeting from Nov 16-20, 2020.
Nov 09, 2020 04:12 pm ET
Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that the company will participate in the Society for Immunotherapy of Cancer (SITC) Annual Meeting online, November 11-14, including poster presentations on November 11th – 13th.
Nov 05, 2020 04:01 pm ET
Personalis Reports Third Quarter 2020 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported financial results for the third quarter ended September 30, 2020.
Oct 27, 2020 04:01 pm ET
Personalis to Participate in Upcoming Investor Conferences
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate in the following upcoming investor conferences.
Oct 22, 2020 04:01 pm ET
Personalis to Announce Third Quarter 2020 Financial Results on November 5, 2020
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced it will release its third quarter 2020 financial results after the market closes on Thursday, November 5, 2020. In conjunction with the release, the Company will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.
Oct 15, 2020 09:02 am ET
Personalis to Participate in Immuno Series US Virtual Meeting
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the company’s participation at the Immuno Series US Virtual meeting which will be held online, October 15-16, 2020.
Oct 01, 2020 01:20 pm ET
Personalis, Inc. to Present at IO Combinations 360˚
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the company’s participation at IO Combinations 360˚ which will be held online, October 1-2, 2020.
Sep 29, 2020 04:05 pm ET
Personalis to Participate in Digital World CB & CDx Meeting
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the company’s participation at the Digital World CB & CDx meeting which will be held online, September 29-October 1, 2020.
Sep 17, 2020 08:03 am ET
Personalis Receives Contract Extension and New Task Order From the VA’s Million Veteran Program – Total Awarded to Date Now $175M
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, announces that the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP) has exercised its option to extend our existing contract through September 2021. The VA also issued a new task order with an approximate value of up to $31M, and it has the right to issue additional task orders through the duration of the contract extension. Realizing revenue from this contract is subject to the receipt of samples from the VA MVP and performance of services by Personalis. The cumulative valu
Sep 15, 2020 04:01 pm ET
Personalis Strengthens Commercial Team with the Appointment of New Head of Population Genomics
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced the appointment of Kevin Dunne as its new Head of Population Genomics.
Sep 02, 2020 04:01 pm ET
Personalis to Participate in Upcoming Investor Conferences
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate in the following upcoming investor conferences.
Aug 12, 2020 04:01 pm ET
Personalis to Participate at the Needham Virtual Cancer Diagnostics 1x1 Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate in the 1-on-1 meetings at the upcoming Needham Virtual Cancer Diagnostics 1x1 Conference on Tuesday, August 18, 2020.
Aug 12, 2020 02:20 am ET
Personalis Announces Pricing of Public Offering of Common Stock
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced the pricing of its previously announced underwritten public offering of 6,578,947 shares of its common stock at a price to the public of $19.00 per share. Gross proceeds to Personalis from the offering are expected to be $125 million, before deducting underwriting discounts and commissions and estimated offering expenses.
Aug 11, 2020 04:26 pm ET
Personalis Announces Launch of Public Offering of Common Stock
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that it has commenced an underwritten public offering of $100 million of its common stock. In addition, Personalis expects the underwriters to be granted a 30-day option to purchase up to an additional $15 million of common stock from a selling stockholder on the same terms and conditions. Personalis will not receive any proceeds from any sale of shares by the selling stockholder.
Aug 06, 2020 04:01 pm ET
Personalis Reports Second Quarter 2020 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today reported financial results for the second quarter ended June 30, 2020.
Aug 03, 2020 08:17 am ET
Personalis, Inc. Launches NeXT Liquid Biopsy™, A High-Performance, Exome-Wide Liquid Biopsy Platform
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of NeXT Liquid Biopsy, a high-performance, exome-scale, tumor-profiling platform that utilizes blood samples from advanced-stage solid tumor cancer patients. NeXT Liquid Biopsy, paired with Personalis’ leading ImmunoID NeXT™ tissue profiling platform, enables a more comprehensive immuno-genomics view of the tumor that can now be monitored over time from blood samples. NeXT Liquid Biopsy monitors over twenty times more genes than the majority of liquid biopsy cancer panels on the market today.
Jul 23, 2020 04:01 pm ET
Personalis to Announce Second Quarter 2020 Financial Results on August 6, 2020
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced it will release its second quarter 2020 financial results after the market closes on Thursday, August 6, 2020. In conjunction with the release, the Company will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.
Jul 16, 2020 05:15 pm ET
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Personalis, Inc. (Nasdaq:PSNL), a leader in advanced genomics for cancer, today announced that, effective on July 15, 2020, the Compensation Committee of its Board of Directors granted non-qualified stock options to purchase an aggregate of 44,600 shares of its common stock and restricted stock units (RSUs) covering an aggregate of 34,800 shares of its common stock to seven new employees under Personalis’ 2020 Inducement Plan.
Jul 16, 2020 08:32 am ET
Personalis Further Expands Leadership Team With Appointment of Leslie Grab, VP of Intellectual Property and John Lyle, VP of Assay Research and Development
Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced the appointment of Leslie Grab as VP of Intellectual Property and John Lyle as VP of Assay Research and Development.
Jul 03, 2020 05:55 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Personalis, Inc. - PSNL
Pomerantz LLP is investigating claims on behalf of investors of Personalis, Inc.  (“Personalis” or the “Company”) (NASDAQ: PSNL).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Jun 24, 2020 05:43 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Personalis, Inc. - PSNL
NEW YORK, June 24, 2020 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of Personalis, Inc.  ("Personalis" or the "Company") (NASDAQ: PSNL).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jun 24, 2020 05:43 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Personalis, Inc. - PSNL
NEW YORK, June 24, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Personalis, Inc.  ("Personalis" or the "Company") (NASDAQ: PSNL).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jun 24, 2020 08:00 am ET
Personalis Completes Sequencing 75,000th Whole Human Genome for VA MVP
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced its completion of the 75,000th whole human genome sequenced under its contract with the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). All genomes were sequenced in the company’s laboratory in Menlo Park, California. With over 825,000 veterans enrolled to date and a recently increased target of two million enrollees, the VA MVP is the largest population sequencing program in the U.S. today.
Jun 22, 2020 06:57 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Personalis, Inc. - PSNL
Pomerantz LLP is investigating claims on behalf of investors of Personalis, Inc.  (“Personalis” or the “Company”) (NASDAQ: PSNL). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Jun 22, 2020 08:00 am ET
Personalis Announces New Data to be Presented at AACR Virtual Scientific Meeting
Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced that the company will present new data in scientific posters to be presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II, which will be held online, June 22-24, 2020.
Jun 18, 2020 06:15 pm ET
Personalis to Participate in European Association for Cancer Research (EACR) 2020 Virtual Congress
Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced the company’s participation in the European Association for Cancer Research (EACR) 2020 Virtual Congress, which will be held online, June 18-19, 2020.
Jun 16, 2020 03:28 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Personalis, Inc. - PSNL
Pomerantz LLP is investigating claims on behalf of investors of Personalis, Inc.  (“Personalis” or the “Company”) (NASDAQ: PSNL).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Jun 16, 2020 01:00 pm ET
Personalis to Present at the Precision Breast Cancer Summit
Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced the company’s participation at the Precision: Breast Cancer Summit, which will be held online, June 16-17, 2020.
Jun 16, 2020 08:00 am ET
Personalis Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Personalis, Inc. (Nasdaq:PSNL), a leader in advanced genomics for cancer, today announced that, effective on June 15, 2020, the Compensation Committee of its Board of Directors granted non-qualified stock options to purchase an aggregate of 67,900 shares of its common stock and restricted stock units (RSUs) covering an aggregate of 52,000 shares of its common stock to 12 new employees under Personalis’ 2020 Inducement Plan.
Jun 10, 2020 04:41 pm ET
CORRECTION – SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Personalis, Inc. - PSNL
In a release issued under the same headline earlier today by Pomerantz LLP, please note that in the first sentence of the first paragraph, the investigation is on behalf of investors of Personalis, Inc. rather than Provident Financial Services,...
Jun 10, 2020 04:05 pm ET
Personalis Announces a Partnership with Berry Genomics for China Expansion
Personalis, Inc. (Nasdaq:PSNL), a leader in advanced genomics for cancer, today announced the partnership with Berry Genomics, headquartered in the People’s Republic of China.
Jun 08, 2020 05:41 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Personalis, Inc. - PSNL
Pomerantz LLP is investigating claims on behalf of investors of Provident Financial Services, Inc. (“Personalis” or the “Company”) (NASDAQ: PSNL). Such investors are advised to contact Robert S. Willoughby at [email protected] or...
Jun 02, 2020 02:41 pm ET
PSNL Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Personalis, Inc. and Encourages Investors to Contact the Firm
NEW YORK, June 2, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Personalis, Inc. ("Personalis" or "the Company") (NASDAQ: PSNL). Investors who purchased Personalis securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/psnl.
Jun 02, 2020 08:00 am ET
Personalis Announces Scientific Collaboration with Sarepta Therapeutics on Immune Response to Precision Genetic Therapeutics
Personalis, Inc. (Nasdaq: PSNL) today announced a collaboration with Sarepta Therapeutics (Nasdaq: SRPT), a leader in precision genetic medicine for rare disease. As part of this research collaboration, Sarepta will be working with the Personalis team to characterize immune response to precision genetic therapeutics, utilizing Personalis’ advanced proprietary analytics.
Jun 01, 2020 03:34 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Personalis, Inc. - PSNL
Pomerantz LLP is investigating claims on behalf of investors of Provident Financial Services, Inc.  (“Personalis” or the “Company”) (NASDAQ: PSNL).  Such investors are advised to contact Robert S. Willoughby at [email protected] or...
May 29, 2020 11:08 am ET
Personalis, Inc. Announces New Data to be Presented at ASCO Virtual Scientific Meeting
Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced that the company will present new data in abstracts to be presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Meeting, which will be held May 29-31, 2020.
May 28, 2020 02:06 pm ET
PERSONALIS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Personalis, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Personalis, Inc. (“Personalis” or the “Company”) (NASDAQ:PSNL). If you invested in Personalis stock or options and would like to discuss your...
May 28, 2020 11:12 am ET
Personalis Shareholders Who Have Suffered Losses Greater Than $50K Encouraged To Contact Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is investigating Personalis, Inc. (“Personalis” or the “Company”) (NASDAQ: PSNL) for potential federal securities law violations pursuant to the Company’s June 2019 initial public offering (“IPO”). Personalis completed its IPO...
May 21, 2020 03:46 pm ET
Shareholder Alert: Robbins LLP Reminds Investor It Is Investigating the Officers and Directors of Personalis, Inc. (PSNL) on Behalf of Shareholders
Shareholder rights law firm Robbins LLP reminds investors it is investigating Personalis, Inc. (NYSE: PSNL) for potential violations of federal securities laws pursuant to its June 2019 initial public offering ("IPO"). Personalis completed its IPO on June 20, 2019, offering shares at $17.00 and raising $140 million in gross proc
May 07, 2020 04:01 pm ET
Personalis Reports First Quarter 2020 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today reported financial results for the first quarter ended March 31, 2020.
May 05, 2020 02:00 pm ET
Personalis, Inc. Appoints Industry Veteran Stephen Moore as General Counsel
Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced the appointment Stephen Moore as General Counsel.
Apr 29, 2020 04:05 pm ET
Personalis to Participate at Upcoming Investor Conferences
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate in three upcoming virtual investor conferences.
Apr 29, 2020 02:55 pm ET
Shareholder Alert: Robbins LLP Announces It Is Investigating the Officers and Directors of Personalis, Inc. (PSNL) on Behalf of Shareholders
Shareholder rights law firm Robbins LLP announces it is investigating Personalis, Inc. (NYSE: PSNL) for potential violations of federal securities laws pursuant to its June 2019 initial public offering ("IPO"). Personalis completed its IPO on June 20, 2019, offering shares at $17.00 and raising $140 million in gross proceeds. Four days
Apr 29, 2020 12:00 pm ET
Personalis Announces Renewed Clinical Laboratory Accreditation from College of American Pathologists
Personalis, Inc. (Nasdaq:PSNL), a leader in advanced genomics for cancer, today announced the Accreditation Committee of the College of American Pathologists (CAP) has awarded re-accreditation to the Personalis Clinical Laboratory, Menlo Park, California based on results of a recent on-site inspection as part of
Apr 23, 2020 04:05 pm ET
Personalis to Announce First Quarter 2020 Financial Results on May 7, 2020
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced it will release its first quarter 2020 financial results after the market closes on Thursday, May 7, 2020. In conjunction with the release, the Company will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.
Apr 21, 2020 11:31 am ET
Indivumed, Personalis Partner to Enhance Genomic Sequencing Capabilities
Indivumed GmbH (“Indivumed”) and Personalis, Inc. (Nasdaq: PSNL) today announced that the two companies have entered into a collaboration in the field of personalized oncology. The partnership seeks to enable novel discoveries in cancer biology by pairing IndivuType, Indivumed’s multiomics cancer database, with genome and transcriptome-level data from thousands of samples using Personalis’ advanced cancer genomics technology.
Apr 21, 2020 03:00 am ET
Indivumed, Personalis Partner to Enhance Genomic Sequencing Capabilities
HAMBURG, Germany and MENLO PARK, Calif., April 21, 2020 /PRNewswire/ -- Indivumed GmbH ("Indivumed") and Personalis, Inc. (Nasdaq: PSNL) today announced that the two companies have entered into a collaboration in the field of personalized oncology. The partnership seeks to enable novel discoveries in cancer biology by pairing IndivuType, Indivumed's multiomics cancer database, with genome and transcriptome-level data from thousands of samples using Personalis' advanced cancer genomics technology.
Apr 16, 2020 03:05 pm ET
Scott+Scott Attorneys at Law LLP Announces Investigation into Personalis, Inc. (PSNL)
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, is investigating whether Personalis, Inc. (“Personalis” or the “Company”) (NASDAQ: PSNL) or certain of its officers and directors violated federal securities laws. If you purchased o
Apr 14, 2020 11:45 am ET
Personalis, Inc. Expands Genomics Portfolio Across Disease Areas With Launch of Pharma Research Solutions for Use in Early Drug Discovery and Preclinical Studies
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of their Pharma Research Solutions, the latest expansion of the company’s portfolio of comprehensive genomics assays and analytics. These solutions, which leverage Personalis’ patented ACE Technology, are designed for use in early drug discovery and preclinical studies in oncology, but also other disease areas. These offerings complement Personalis’ comprehensive immunogenomics platform, ImmunoID NeXT™, which is currently used for clinical biomarker and companion diagnostic development in tran
Mar 31, 2020 04:05 pm ET
Personalis to Participate at the 19th Annual Needham Virtual Healthcare Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate in the 1-on-1 meetings at the upcoming 19th Annual Needham Virtual Healthcare Conference from Tuesday, April 14, 2020 through Wednesday, April 15, 2020.
Mar 25, 2020 04:01 pm ET
Personalis Reports Fourth Quarter and Full Year 2019 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today reported financial results for the fourth quarter and full year ended December 31, 2019.
Mar 11, 2020 04:05 pm ET
Personalis to Announce Fourth Quarter and Full Year 2019 Financial Results on March 25, 2020
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced it will release its fourth quarter and full year 2019 financial results after the market closes on Wednesday, March 25, 2020. In conjunction with the release, the Company will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.
Feb 26, 2020 08:00 am ET
Personalis, Inc. to Present at Immuno-Oncology 360˚ Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present at Immuno-Oncology 360˚ conference in New York, February 26-28.
Feb 18, 2020 04:05 pm ET
Personalis, Inc. to Present at Biomarkers Series UK 2020 Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present at the Biomarkers Series UK 2020 conference in Manchester, UK, February 19-20.
Feb 18, 2020 08:00 am ET
Personalis to Participate at the Cowen 40th Annual Health Care Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate at the upcoming Cowen 40th Annual Health Care Conference.
Feb 11, 2020 01:00 pm ET
Advaxis and Personalis Announce Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program
Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, and Personalis Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced a collaboration to leverage Personalis’ ImmunoID NeXT™ Platform in Advaxis’ ongoing Phase 1/2 ADXS-503 (HOT Lung) program evaluating ADXS-503 alone and in combination with pembrolizumab in patients with non-small cell lung cancer (NSCLC). The ADXS-503 construct targets 11 public or shared hotspot neoantigens in KRAS, EGFR and TP53 as well as 11 proprietary tu
Feb 11, 2020 08:00 am ET
Advaxis and Personalis Announce Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program
Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, and Personalis Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced a...
Jan 22, 2020 12:15 pm ET
Personalis, Inc. to Present at Precision Medicine World Conference 2020
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the Precision Medicine World Conference (PMWC) 2020 in Santa Clara, CA January 22-24.
Jan 07, 2020 05:15 pm ET
Personalis, Inc. Announces the Launch of the NeXT Dx™ Test, a Comprehensive Genomic Cancer Profiling Test Enabling Advanced Composite Biomarkers for Cancer Treatment
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of the NeXT Dx™ Test to help oncologists identify potential therapies and clinical trial options for cancer patients. The Personalis NeXT Dx™ Test is one of the first cancer diagnostic platforms to profile approximately 20,000 genes in both the tumor exome and transcriptome, providing a comprehensive genomic testing solution that goes beyond many existing cancer diagnostic panels that focus on a few hundred genes. The Personalis NeXT Dx Test includes advanced analytics to provide a diagnostic
Dec 10, 2019 08:00 pm ET
Personalis, Inc. to Present at ESMO Immuno-Oncology Congress 2019
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the ESMO Immuno-Oncology Congress 2019 in Geneva, Switzerland, December 11-14, including a poster presentation on December 12th.
Nov 21, 2019 08:00 am ET
Personalis, Inc. to Present at NeoAg Summit US 2019
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present at the NeoAg Summit US 2019 in Boston on November 21st at 9:15 AM EST.
Nov 19, 2019 04:05 pm ET
Personalis to Present at Upcoming Investor Conferences
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that Aaron Tachibana, Chief Financial Officer and Clinton Musil, Chief Business Officer, are scheduled to present at the following upcoming investor conferences.
Nov 19, 2019 08:00 am ET
Personalis, Inc. Announces Collaboration With Merck KGaA, Darmstadt, Germany, to Identify and Develop Novel Biomarkers for Cancer Therapies
Personalis, Inc. (Nasdaq:PSNL), a leader in advanced genomics for cancer, today announced a collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company, to investigate novel biomarkers of response and mechanisms of resistance to cancer therapies. Merck KGaA, Darmstadt, Germany, will utilize Personalis’ newest cancer immunogenomics platform, ImmunoID NeXT™, for clinical biomarker identification and development.
Nov 17, 2019 04:30 pm ET
Personalis, Inc. to Present New Data at the AACR Tumor Immunology and Immunotherapy Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the AACR Tumor Immunology and Immunotherapy conference at the Boston Marriott Copley Place in Boston, MA, November 17-20, including poster presentations on
Nov 13, 2019 04:05 pm ET
Personalis Reports Third Quarter 2019 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today reported financial results for the third quarter ended September 30, 2019.
Nov 12, 2019 05:30 pm ET
Personalis, Inc. Expands Oncology Portfolio With the Launch of Cancer Whole Genome Sequencing Services
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of Personalis’ Cancer Whole Genome Sequencing which further extends Personalis’ portfolio of comprehensive cancer genomics services designed to maximize biological insights from tumor samples.
Nov 06, 2019 01:15 pm ET
Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, MD, November 7-10, including poster presentations on November 8th and 9th.
Oct 30, 2019 04:05 pm ET
Personalis to Announce Third Quarter 2019 Financial Results on November 13, 2019
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced it will release its third quarter 2019 financial results after the market closes on Wednesday, November 13, 2019. In conjunction with the release, the Company will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.
Oct 24, 2019 11:00 am ET
Personalis, Inc. to Present at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019 in Boston, October 27-30, including a poster presentation on October 27th.
Oct 08, 2019 11:00 am ET
Personalis, Inc. to Present at Advances in Immuno-Oncology Congress USA 2019
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present at Advances in Immuno-Oncology Congress USA 2019 in San Diego on October 8th at 2:50 PM PDT.
Sep 26, 2019 04:05 pm ET
Personalis Receives New Order from the VA’s Million Veteran Program – Total Awarded to Date Now $145M
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced a new task order under its contract with the U.S. Department of Veterans Affairs (VA) for the VA’s Million Veteran Program (VA MVP). The new task order is effective on September 28, 2019. This is the largest single task order received to date and has a value of up to approximately $38.1M, subject to the receipt of samples from the VA MVP and performance of services by Personalis. The cumulative value of task orders received to date from the VA MVP has increased to approximately $145M.
Sep 12, 2019 04:07 pm ET
Personalis Appoints Karin Eastham to Its Board of Directors
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that it has appointed Karin Eastham as an independent director to its Board of Directors. Ms. Eastham brings more than 36 years of experience as both an executive and as an independent director in the biotechnology industry, with deep expertise in finance and operations. From May 2004 until her retirement in September 2008, Ms. Eastham served as Executive Vice President and Chief Operating Officer, and as a member of the Board of Trustees, of the Burnham Institute for Medical Research (now Sanford Burnha
Sep 09, 2019 08:00 am ET
Personalis, Inc. Enters Into Research Agreement With Invectys to Provide Comprehensive Tumor Immunogenomics Profiling for Clinical Trial
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that it has entered into a research agreement with Invectys, a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancers. Under the terms of the agreement, Personalis will provide comprehensive tumor immunogenomics capabilities to facilitate biomarker discovery in chronic lymphocytic leukemia (CLL) patients enrolled in a Phase II clinical trial assessing the efficacy of INVAC-1, a DNA plasmid encoding a modified human telomerase reverse transcriptase (hT
Aug 26, 2019 04:32 pm ET
Personalis to Participate in the 17th Annual Morgan Stanley Global Healthcare Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the company will participate at the upcoming 17th Annual Morgan Stanley Global Healthcare Conference being held from September 9-11, 2019 in New York, NY.
Aug 13, 2019 04:02 pm ET
Personalis Reports Second Quarter 2019 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today reported financial results for the second quarter ended June 30, 2019.
Aug 07, 2019 08:00 am ET
Personalis, Inc. to Provide Comprehensive Tumor Immunogenomic Profiling to the New Mexico Cancer Care Alliance for Clinical Study
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that The University of New Mexico (UNM) Comprehensive Cancer Center and the New Mexico Alliance for Cancer Care will utilize Personalis’ cancer immunogenomics platform, ImmunoID NeXT™, for the investigation of biomarkers of response to a novel treatme
Aug 01, 2019 04:05 pm ET
Personalis, Inc. Announces Integration of New ImmunoID NeXT Platform™ Features in Latest Expansion of Immuno-Oncology Biomarker Discovery Applications
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the latest expansion of its universal cancer immunogenomics platform, ImmunoID NeXT, incorporating several additional features that are pivotal to the understanding of tumor and immune cell interactions and how the nature of these interactions can imp
Jul 30, 2019 08:00 am ET
Personalis to Announce Second Quarter 2019 Financial Results on August 13, 2019
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced it will release its second quarter 2019 financial results after the market closes on Tuesday, August 13, 2019. In conjunction with the release, the Company will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.